CHICAGO, Oct. 2, 2014 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO) today announced that, through its distributor in Brazil, Semina Industria e Comercio Ltda (Semina), it has been awarded an exclusive contract under a public tender to supply up to 50 million FC2 Female Condoms® to the Brazilian Ministry of Health. The contract is valid through August 20, 2015, and the Ministry of Health will place orders against this tender at their discretion.
"This contract reflects Brazil's leadership in providing women with options to protect their health and control their reproductive choices," noted Karen King, President and Chief Executive Officer of The Female Health Company. "Brazil has demonstrated true global leadership with its exemplary HIV/AIDS prevention program and a strong commitment to empowering women to take control of their health and wellness."
"This tender process was competitive, and we are pleased that the total value proposition provided by The Female Health Company and its distribution partner, Semina, was recognized by the Brazilian Ministry of Health. We are proud to serve the Brazilian government in offering this important tool for protecting the women of Brazil against sexually transmitted diseases."
Additionally, FHC and Semina have agreed to reinitiate discussions regarding local production of FC2 in Brazil.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, it has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
About Semina Indústria e Comércio
Semina Industria e Comercio Ltda, based in Sao Paulo, Brazil, is FHC's exclusive distributor of FC2 Female Condoms in Brazil. Semina also manufactures and distributes silicon diaphragms, breastfeeding and other female health products. Semina is also a leading developer and distributor of educational materials focused on reproductive health and family planning. Semina subscribes to the highest international standards of quality and holds certifications of Good Manufacturing Practices and Distribution and its products are duly registered with ANVISA (Brazilian Regulatory Sanitary Agency).
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release relate to the timing and amount of orders under the Brazil contract and possible local production of FC2 in Brazil. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, the risk that government tenders and contracts may be subject to cancellation, delay or restructuring and that government ministries or other public sector customers may order and purchase fewer units than the full maximum tender or contract amount; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; the Company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives, the Company's ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2013. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health CompanyRELATED LINKS
Press Release Kari Sharp